Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cyclosporin in ophthalmology]

J M Rakic1

  • 1C.H.U. Sart-Tilman, Ophtalmologie, Liège, Belgique.

Bulletin De La Societe Belge D'Ophtalmologie
|January 1, 1993
PubMed
Summary

Topical cyclosporine A (CsA) offers a safer alternative to systemic use for eye conditions, reducing side effects. However, limited ocular penetration restricts its use in certain immune-related eye diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Tear your eyes out ! A case of bilateral auto-enucleation].

Revue medicale de Liege·2022
Same author

[Bilateral diffuse uveal melanocytic proliferation : a rare paraneoplasic syndrome to be diagnosed early].

Revue medicale de Liege·2021
Same author

[What's new in diabetic retinopathy ?]

Revue medicale de Liege·2020
Same author

[Post-traumaticaniridia long after cataract surgery].

Revue medicale de Liege·2020
Same author

[Unilateral pigmentary retinopathy : about 2 cases].

Revue medicale de Liege·2019
Same author

[Painful Horner's syndrome revealing carotid artery dissection : about four cases].

Revue medicale de Liege·2018

Area of Science:

  • Immunology
  • Ophthalmology
  • Pharmacology

Context:

  • Cyclosporine A (CsA) is an immunosuppressant targeting T-cells.
  • Systemic CsA use for transplantation and uveitis is linked to significant nephrotoxicity.
  • Steroids inhibit the phagocytic system more than CsA.

Purpose:

  • To evaluate the safety and efficacy of topical CsA in olive oil for ocular conditions.
  • To explore the potential of topical CsA as an alternative to systemic administration.
  • To identify limitations in ocular penetration for CsA's therapeutic applications.

Summary:

  • Topical administration of 2% CsA in olive oil demonstrates reduced systemic side-effects and good local tolerability.
  • Ocular penetration of topical CsA is a key factor limiting its use.
  • CsA is a selective T-cell immunosuppressant with a different mechanism than steroids.

Impact:

  • Topical CsA presents a safer therapeutic option for specific ocular immune diseases.
  • Improved ocular drug delivery could expand the indications for CsA in ophthalmology.
  • Understanding CsA's pharmacokinetic profile is crucial for optimizing its clinical use.

Related Experiment Videos